209 related articles for article (PubMed ID: 17253876)
1. Open-label extension studies: do they provide meaningful information on the safety of new drugs?
Day RO; Williams KM
Drug Saf; 2007; 30(2):93-105. PubMed ID: 17253876
[TBL] [Abstract][Full Text] [Related]
2. Design, objectives, execution and reporting of published open-label extension studies.
Megan B; Pickering RM; Weatherall M
J Eval Clin Pract; 2012 Apr; 18(2):209-15. PubMed ID: 21040252
[TBL] [Abstract][Full Text] [Related]
3. Pharmacoepidemiology in pre-approval clinical trial safety monitoring.
Guess HA
J Clin Epidemiol; 1991; 44(8):851-7. PubMed ID: 1941038
[TBL] [Abstract][Full Text] [Related]
4. Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.
Drugs R D; 2005; 6(3):178-85. PubMed ID: 15869322
[TBL] [Abstract][Full Text] [Related]
5. Long-term migraine prevention with topiramate: open-label extension of pivotal trials.
Rapoport A; Mauskop A; Diener HC; Schwalen S; Pfeil J
Headache; 2006; 46(7):1151-60. PubMed ID: 16866719
[TBL] [Abstract][Full Text] [Related]
6. American Society of Clinical Oncology policy statement: oversight of clinical research.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
[TBL] [Abstract][Full Text] [Related]
7. Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.
Drugs R D; 2005; 6(2):120-7. PubMed ID: 15777106
[TBL] [Abstract][Full Text] [Related]
8. ISA 247: trans-ISA 247, trans-R 1524, ISA(TX)247, ISAtx 247, ISATx247, LX 211, LX211, R 1524, R-1524.
Drugs R D; 2007; 8(2):103-12. PubMed ID: 17324008
[TBL] [Abstract][Full Text] [Related]
9. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
10. Open label extension studies and patient selection biases.
Hemming K; Hutton JL; Maguire MJ; Marson AG
J Eval Clin Pract; 2008 Feb; 14(1):141-4. PubMed ID: 18211657
[TBL] [Abstract][Full Text] [Related]
11. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension.
Trenkwalder C; Beneš H; Grote L; García-Borreguero D; Högl B; Hopp M; Bosse B; Oksche A; Reimer K; Winkelmann J; Allen RP; Kohnen R;
Lancet Neurol; 2013 Dec; 12(12):1141-50. PubMed ID: 24140442
[TBL] [Abstract][Full Text] [Related]
12. Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits.
Fountzilas E; Said R; Tsimberidou AM
Expert Opin Investig Drugs; 2018 Feb; 27(2):155-162. PubMed ID: 29353505
[TBL] [Abstract][Full Text] [Related]
13. Safety profile and tolerability of up to 1 year of pregabalin treatment in 3 open-label extension studies in patients with fibromyalgia.
Arnold LM; Emir B; Murphy TK; Zeiher BG; Pauer L; Scott G; Petersel D
Clin Ther; 2012 May; 34(5):1092-102. PubMed ID: 22503162
[TBL] [Abstract][Full Text] [Related]
14. Causality Assessment in Premarketing Drug Clinical Trials: Regulatory Evolution in the USA and Ongoing Concerns.
Goldman SA
Drug Saf; 2016 Oct; 39(10):895-901. PubMed ID: 27473417
[TBL] [Abstract][Full Text] [Related]
15. An analysis of safety data from five phase III clinical trials on the use of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
Rubin M; Dover J; Maas C; Nestor M
Aesthet Surg J; 2009 Nov; 29(6 Suppl):S50-6. PubMed ID: 19945005
[TBL] [Abstract][Full Text] [Related]
16. Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25.
BioDrugs; 2002; 16(5):380-6. PubMed ID: 12408744
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel.
Montouris G; Yang H; Williams B; Zhou S; Laurenza A; Fain R
Epilepsy Res; 2015 Aug; 114():131-40. PubMed ID: 26088896
[TBL] [Abstract][Full Text] [Related]
18. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
Bone HG; Wagman RB; Brandi ML; Brown JP; Chapurlat R; Cummings SR; Czerwiński E; Fahrleitner-Pammer A; Kendler DL; Lippuner K; Reginster JY; Roux C; Malouf J; Bradley MN; Daizadeh NS; Wang A; Dakin P; Pannacciulli N; Dempster DW; Papapoulos S
Lancet Diabetes Endocrinol; 2017 Jul; 5(7):513-523. PubMed ID: 28546097
[TBL] [Abstract][Full Text] [Related]
19. Safety pharmacology--a progressive approach.
Redfern WS; Wakefield ID; Prior H; Pollard CE; Hammond TG; Valentin JP
Fundam Clin Pharmacol; 2002 Jun; 16(3):161-73. PubMed ID: 12165064
[TBL] [Abstract][Full Text] [Related]
20. Legal and ethical obligations to conduct a clinical drug trial in Australia as an investigator initiated and sponsored study for an overseas pharmaceutical company.
Beran RG
Med Law; 2004; 23(4):913-24. PubMed ID: 15685926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
